CA3052538A1 - Humanized antibodies that bind tau protein phosphorylated at serine 413 and use therefor to treat tauopathies - Google Patents

Humanized antibodies that bind tau protein phosphorylated at serine 413 and use therefor to treat tauopathies Download PDF

Info

Publication number
CA3052538A1
CA3052538A1 CA3052538A CA3052538A CA3052538A1 CA 3052538 A1 CA3052538 A1 CA 3052538A1 CA 3052538 A CA3052538 A CA 3052538A CA 3052538 A CA3052538 A CA 3052538A CA 3052538 A1 CA3052538 A1 CA 3052538A1
Authority
CA
Canada
Prior art keywords
seq
sequence
antibody
amino acid
tau
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3052538A
Other languages
English (en)
French (fr)
Inventor
Hiroshi Eguchi
Takashi Murakami
Naoko NAMIKI
Akira Tanokura
Jeanne E. Baker
Sophie PARMENTIER BATTEUR
Angela Marie Jablonski
Daniel Stephen Malashock
Carl Mieczkowski
Gopalan RAGHUNATHAN (raghu)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Teijin Pharma Ltd
Merck Sharp and Dohme LLC
Original Assignee
Teijin Pharma Ltd
Merck Sharp and Dohme LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teijin Pharma Ltd, Merck Sharp and Dohme LLC filed Critical Teijin Pharma Ltd
Publication of CA3052538A1 publication Critical patent/CA3052538A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies from serum
    • C07K16/065—Purification, fragmentation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA3052538A 2017-02-27 2018-02-27 Humanized antibodies that bind tau protein phosphorylated at serine 413 and use therefor to treat tauopathies Pending CA3052538A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2017035594A JP2018139530A (ja) 2017-02-27 2017-02-27 認知症治療又は予防のためのヒト化抗体及びその製造方法、並びにそれを用いた認知症治療剤又は予防剤
JPJP2017-035594 2017-02-27
PCT/IB2018/000249 WO2018154390A1 (en) 2017-02-27 2018-02-27 Humanized antibody for treating or preventing cognitive disorders, process for producing the same, and agent for treating or preventing cognitive disorders using the same

Publications (1)

Publication Number Publication Date
CA3052538A1 true CA3052538A1 (en) 2018-08-30

Family

ID=62025891

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3052538A Pending CA3052538A1 (en) 2017-02-27 2018-02-27 Humanized antibodies that bind tau protein phosphorylated at serine 413 and use therefor to treat tauopathies

Country Status (27)

Country Link
US (3) US10556950B2 (https=)
EP (1) EP3585810B1 (https=)
JP (4) JP2018139530A (https=)
KR (1) KR102701634B1 (https=)
CN (2) CN111320695B (https=)
AR (2) AR110875A1 (https=)
AU (1) AU2018224390C1 (https=)
BR (1) BR112019016490A2 (https=)
CA (1) CA3052538A1 (https=)
CL (3) CL2019002296A1 (https=)
CO (1) CO2019008786A2 (https=)
CR (1) CR20190363A (https=)
DO (1) DOP2019000215A (https=)
EA (1) EA201991726A1 (https=)
ES (1) ES3063126T3 (https=)
GE (2) GEP20227392B (https=)
IL (1) IL267945B2 (https=)
JO (1) JOP20180014A1 (https=)
MA (1) MA47608A (https=)
MX (2) MX2019009945A (https=)
MY (1) MY193821A (https=)
NI (1) NI201900086A (https=)
PE (2) PE20191614A1 (https=)
PH (1) PH12019501929A1 (https=)
SG (2) SG10201913419TA (https=)
TW (2) TWI848904B (https=)
WO (2) WO2018154392A1 (https=)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2857039T3 (pl) * 2012-05-31 2020-05-18 Osaka City University Środek terapeutyczny lub środek profilaktyczny na otępienie
SG11201907422RA (en) 2017-02-17 2019-09-27 Denali Therapeutics Inc Anti-tau antibodies and methods of use thereof
JP2018139530A (ja) 2017-02-27 2018-09-13 帝人ファーマ株式会社 認知症治療又は予防のためのヒト化抗体及びその製造方法、並びにそれを用いた認知症治療剤又は予防剤
AU2018352308B2 (en) 2017-10-16 2025-06-05 Eisai R&D Management Co., Ltd. Anti-tau antibodies and uses thereof
US20210355199A1 (en) 2018-06-28 2021-11-18 University Of Virginia Patent Foundation Compositions and methods for detecting and regulating fibronectin-integrin interaction and signaling
US12365724B2 (en) * 2018-12-10 2025-07-22 New York University Antibodies binding to phospho-tau comprising phosphorylated Ser396 and Ser404 and methods of detecting thereof
US20220381790A1 (en) 2019-02-11 2022-12-01 University Of Virginia Patent Foundation Selection and blockade of fertilization competent male and female gametes
EP3934677A4 (en) 2019-03-13 2022-11-16 University of Virginia Patent Foundation COMPOSITIONS AND METHODS TO PROMOTE ISLAND VIABILITY AND INCREASE INSULINE SECRETION
JP7181438B2 (ja) * 2019-08-06 2022-11-30 アプリノイア セラピューティクス リミテッド 病理学的タウ種に結合する抗体及びその使用
CN115605594A (zh) * 2020-06-02 2023-01-13 帝人制药株式会社（Jp） 抗igf-1受体人源化抗体
CA3183835A1 (en) * 2020-06-25 2021-12-30 Jeanne E. Baker High affinity antibodies targeting tau phosphorylated at serine 413
US20250034559A1 (en) 2021-11-17 2025-01-30 Voyager Therapeutics, Inc. Compositions and methods for the treatment of tau-related disorders
CN115322255B (zh) * 2022-04-25 2025-03-07 上海药明生物医药有限公司 一种优化的Fc变体及其应用
KR20250069606A (ko) 2022-09-15 2025-05-19 보이저 테라퓨틱스, 인크. 타우 결합 화합물
WO2025122634A1 (en) 2023-12-05 2025-06-12 Voyager Therapeutics, Inc. Compositions and methods for the treatment of tau-related disorders
WO2025207501A1 (en) * 2024-03-26 2025-10-02 Merck Sharp & Dohme Llc Crystals of anti-human tau monoclonal antibody
CN119080924B (zh) * 2024-07-04 2025-02-25 上海交通大学医学院附属第九人民医院 一种单克隆免疫球蛋白及其用途

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS587390B2 (ja) 1975-03-11 1983-02-09 ツキシマキカイ カブシキガイシヤ ア−クヨウセツホウホウ
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
EP1400536A1 (en) 1991-06-14 2004-03-24 Genentech Inc. Method for making humanized antibodies
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
JP3587390B2 (ja) 1994-03-17 2004-11-10 タカラバイオ株式会社 リン酸化アミノ酸誘導体及びリン酸化ペプチド合成方法
JP4754352B2 (ja) 2003-08-29 2011-08-24 株式会社リバース・プロテオミクス研究所 タンパク質の固定化方法
AU2004297616B2 (en) 2003-12-04 2008-12-18 Xencor, Inc. Methods of generating variant proteins with increased host string content and compositions thereof
UA107571C2 (xx) 2009-04-03 2015-01-26 Фармацевтична композиція
US8609097B2 (en) 2009-06-10 2013-12-17 Hoffmann-La Roche Inc. Use of an anti-Tau pS422 antibody for the treatment of brain diseases
MY164376A (en) 2010-10-07 2017-12-15 Univ Leuven Kath Phosphospecific antibodies recognizing tau
CA2813493C (en) 2010-10-11 2019-07-09 University Of Zurich Human anti-tau antibodies
MX350311B (es) 2011-12-20 2017-09-01 Janssen Biotech Inc Anticuerpos anti-phf-tau y sus usos.
PL2857039T3 (pl) * 2012-05-31 2020-05-18 Osaka City University Środek terapeutyczny lub środek profilaktyczny na otępienie
NZ630542A (en) * 2012-08-16 2017-06-30 Ipierian Inc Methods of treating a tauopathy
CA2896066C (en) 2012-12-21 2022-07-12 Biogen Ma Inc. Human anti-tau antibodies
BR112015030356A2 (pt) 2013-06-10 2017-12-05 Ipierian Inc métodos de tratamento de uma taupatia
AU2014368696A1 (en) 2013-12-20 2016-06-02 F. Hoffmann-La Roche Ag Humanized anti-Tau(pS422) antibodies and methods of use
AR100978A1 (es) * 2014-06-26 2016-11-16 Hoffmann La Roche LANZADERAS CEREBRALES DE ANTICUERPO HUMANIZADO ANTI-Tau(pS422) Y USOS DE LAS MISMAS
TWI734975B (zh) * 2014-06-27 2021-08-01 美商Ｃ２Ｎ醫療診斷有限責任公司 人類化抗-tau抗體
CA2961439A1 (en) 2014-11-05 2016-05-12 Genentech, Inc. Anti-fgfr2/3 antibodies and methods using same
WO2016112078A2 (en) 2015-01-08 2016-07-14 Janssen Biotech, Inc. Anti-phf-tau antibodies and their uses
US10344081B2 (en) 2015-07-06 2019-07-09 Ucb Biopharma Sprl Tau-binding antibodies
WO2017005734A1 (en) 2015-07-06 2017-01-12 Ucb Biopharma Sprl Tau-binding antibodies
JO3711B1 (ar) 2015-07-13 2021-01-31 H Lundbeck As أجسام مضادة محددة لبروتين تاو وطرق استعمالها
JP2018139530A (ja) 2017-02-27 2018-09-13 帝人ファーマ株式会社 認知症治療又は予防のためのヒト化抗体及びその製造方法、並びにそれを用いた認知症治療剤又は予防剤

Also Published As

Publication number Publication date
AR117952A2 (es) 2021-09-08
EA201991726A1 (ru) 2020-01-30
TW202506718A (zh) 2025-02-16
CL2021002389A1 (es) 2022-04-22
AU2018224390A1 (en) 2019-07-11
MY193821A (en) 2022-10-27
JP2018139530A (ja) 2018-09-13
MX2023013246A (es) 2023-11-21
CL2019002296A1 (es) 2019-11-29
JP2020508666A (ja) 2020-03-26
CN111320695B (zh) 2021-09-03
CL2024000339A1 (es) 2024-08-16
CN110382528A (zh) 2019-10-25
AR110875A1 (es) 2019-05-08
US10894829B2 (en) 2021-01-19
CO2019008786A2 (es) 2019-08-20
JOP20180014A1 (ar) 2019-01-30
CR20190363A (es) 2019-11-05
JP2023002670A (ja) 2023-01-10
GEP20227392B (en) 2022-06-27
AU2018224390C1 (en) 2025-04-17
BR112019016490A2 (pt) 2020-04-07
GEAP202215170A (en) 2022-02-10
ES3063126T3 (en) 2026-04-15
TWI848904B (zh) 2024-07-21
SG10201913419TA (en) 2020-03-30
JP7165996B2 (ja) 2022-11-07
WO2018154392A1 (en) 2018-08-30
IL267945B1 (en) 2025-06-01
AU2018224390B2 (en) 2024-10-31
NI201900086A (es) 2019-10-08
US20210380677A1 (en) 2021-12-09
US20180346564A1 (en) 2018-12-06
US10556950B2 (en) 2020-02-11
CN111320695A (zh) 2020-06-23
DOP2019000215A (es) 2019-09-30
US20200223916A1 (en) 2020-07-16
EP3585810B1 (en) 2025-11-26
JP2024170459A (ja) 2024-12-10
US11739143B2 (en) 2023-08-29
PH12019501929A1 (en) 2020-06-29
EP3585810A1 (en) 2020-01-01
KR20190122674A (ko) 2019-10-30
IL267945A (en) 2019-09-26
WO2018154390A1 (en) 2018-08-30
IL267945B2 (en) 2025-10-01
TW201843179A (zh) 2018-12-16
PE20191614A1 (es) 2019-11-05
SG11201907548PA (en) 2019-09-27
MA47608A (fr) 2020-01-01
MX2019009945A (es) 2019-11-05
PE20241514A1 (es) 2024-07-19
KR102701634B1 (ko) 2024-08-30

Similar Documents

Publication Publication Date Title
US11739143B2 (en) Humanized antibody for treating or preventing cognitive disorders, process for producing the same, and agent for treating or preventing cognitive disorders using the same
CN114341181B (zh) 抗ms4a4a抗体及其使用方法
US11702467B2 (en) High affinity antibodies targeting tau phosphorylated at serine 413
AU2018344417A1 (en) CD3/CD33 bispecific binding molecules
EA048178B1 (ru) Гуманизированное антитело для лечения или предотвращения когнитивных расстройств, способ его получения и агент для лечения или предотвращения когнитивных расстройств с его применением
EA040482B1 (ru) Гуманизированное антитело для лечения или предотвращения когнитивных расстройств, способ его получения и агент для лечения или предотвращения когнитивных расстройств с его применением
HK40013632A (en) Humanized antibody for treating or preventing cognitive disorders, process for producing the same, and agent for treating or preventing cognitive disorders using the same
BR122024019353A2 (pt) Anticorpos anti-pser413 tau, anticorpos humanizados, molécula de ácido nucleico, vetor ou plasmídeo, composições compreendendo os mesmos, células hospedeiras, métodos para preparação dos referidos anticorpos, uso dos mesmos e agente para tratar ou prevenir demência
WO2026057545A1 (en) Anti-sting antibodies and methods of use thereof
WO2026056998A1 (zh) Gipr结合分子及医药用途

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20220617

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20240823

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION

Effective date: 20241216

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 7TH ANNIV.) - STANDARD

Year of fee payment: 7

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20241221

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20241221

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20241221

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250218

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20250614

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20250614

D22 Grant of ip right intended

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D22-D128 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALLOWANCE REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20251206

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20251210

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 8TH ANNIV.) - STANDARD

Year of fee payment: 8

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20251217

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20251217